Tourmaline Bio (TRML) Competitors $47.88 -0.01 (-0.01%) As of 10:23 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TRML vs. KRYS, PTCT, MENS, ARWR, ACLX, PCVX, CRNX, PTGX, KYMR, and MLTXShould you be buying Tourmaline Bio stock or one of its competitors? The main competitors of Tourmaline Bio include Krystal Biotech (KRYS), PTC Therapeutics (PTCT), Jyong Biotech (MENS), Arrowhead Pharmaceuticals (ARWR), Arcellx (ACLX), Vaxcyte (PCVX), Crinetics Pharmaceuticals (CRNX), Protagonist Therapeutics (PTGX), Kymera Therapeutics (KYMR), and MoonLake Immunotherapeutics (MLTX). These companies are all part of the "pharmaceutical products" industry. Tourmaline Bio vs. Its Competitors Krystal Biotech PTC Therapeutics Jyong Biotech Arrowhead Pharmaceuticals Arcellx Vaxcyte Crinetics Pharmaceuticals Protagonist Therapeutics Kymera Therapeutics MoonLake Immunotherapeutics Krystal Biotech (NASDAQ:KRYS) and Tourmaline Bio (NASDAQ:TRML) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, valuation, institutional ownership, media sentiment, risk, profitability, dividends and analyst recommendations. Is KRYS or TRML more profitable? Krystal Biotech has a net margin of 40.85% compared to Tourmaline Bio's net margin of 0.00%. Krystal Biotech's return on equity of 15.21% beat Tourmaline Bio's return on equity.Company Net Margins Return on Equity Return on Assets Krystal Biotech40.85% 15.21% 13.81% Tourmaline Bio N/A -30.50%-29.63% Do institutionals & insiders have more ownership in KRYS or TRML? 86.3% of Krystal Biotech shares are owned by institutional investors. Comparatively, 91.9% of Tourmaline Bio shares are owned by institutional investors. 13.7% of Krystal Biotech shares are owned by insiders. Comparatively, 13.0% of Tourmaline Bio shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Do analysts recommend KRYS or TRML? Krystal Biotech currently has a consensus target price of $209.00, suggesting a potential upside of 11.42%. Tourmaline Bio has a consensus target price of $45.65, suggesting a potential downside of 4.67%. Given Krystal Biotech's stronger consensus rating and higher possible upside, analysts clearly believe Krystal Biotech is more favorable than Tourmaline Bio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Krystal Biotech 0 Sell rating(s) 2 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.75Tourmaline Bio 1 Sell rating(s) 9 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Does the media refer more to KRYS or TRML? In the previous week, Tourmaline Bio had 2 more articles in the media than Krystal Biotech. MarketBeat recorded 4 mentions for Tourmaline Bio and 2 mentions for Krystal Biotech. Tourmaline Bio's average media sentiment score of 0.79 beat Krystal Biotech's score of 0.67 indicating that Tourmaline Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Krystal Biotech 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Tourmaline Bio 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has better earnings & valuation, KRYS or TRML? Krystal Biotech has higher revenue and earnings than Tourmaline Bio. Tourmaline Bio is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKrystal Biotech$290.52M18.68$89.16M$4.9238.12Tourmaline BioN/AN/A-$73.21M-$3.43-13.96 Which has more volatility and risk, KRYS or TRML? Krystal Biotech has a beta of 0.64, indicating that its share price is 36% less volatile than the S&P 500. Comparatively, Tourmaline Bio has a beta of 2.27, indicating that its share price is 127% more volatile than the S&P 500. SummaryKrystal Biotech beats Tourmaline Bio on 11 of the 15 factors compared between the two stocks. Get Tourmaline Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for TRML and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TRML and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TRML vs. The Competition Export to ExcelMetricTourmaline BioMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.23B$2.65B$6.13B$10.61BDividend YieldN/A56.71%5.69%4.71%P/E Ratio-13.9623.6585.8627.54Price / SalesN/A576.20540.53202.58Price / CashN/A173.2337.9261.55Price / Book4.095.6012.986.78Net Income-$73.21M$32.78M$3.30B$275.79M7 Day Performance0.03%5.66%4.73%2.99%1 Month Performance0.51%13.04%9.96%9.50%1 Year Performance76.18%2.02%84.61%35.97% Tourmaline Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TRMLTourmaline Bio1.5556 of 5 stars$47.890.0%$45.65-4.7%+68.1%$1.23BN/A-13.9644Analyst ForecastKRYSKrystal Biotech4.5219 of 5 stars$176.75+5.3%$209.00+18.2%+7.1%$4.86B$290.52M35.92210Analyst ForecastPTCTPTC Therapeutics3.5072 of 5 stars$60.65+2.8%$69.00+13.8%+58.2%$4.69B$806.78M8.701,410Analyst ForecastInsider TradeMENSJyong BiotechN/A$50.00-16.3%N/AN/A$4.54BN/A0.0031Analyst ForecastARWRArrowhead Pharmaceuticals4.0091 of 5 stars$33.78+3.0%$43.14+27.7%+105.0%$4.53B$572.98M-26.39400Analyst ForecastACLXArcellx2.2524 of 5 stars$79.11-0.8%$114.31+44.5%+9.2%$4.42B$56.98M-23.1380Analyst ForecastPCVXVaxcyte2.4127 of 5 stars$34.65+2.0%$106.25+206.6%-63.5%$4.41BN/A-8.43160News CoverageCRNXCrinetics Pharmaceuticals3.8969 of 5 stars$43.51-5.2%$73.20+68.2%-14.1%$4.32B$1.04M-10.59210Analyst ForecastPTGXProtagonist Therapeutics2.1834 of 5 stars$65.14-3.4%$68.36+4.9%+48.5%$4.19B$434.43M93.06120Analyst ForecastKYMRKymera Therapeutics1.938 of 5 stars$58.50+4.0%$59.95+2.5%+30.8%$4.02B$47.07M-16.86170Analyst ForecastMLTXMoonLake Immunotherapeutics2.9488 of 5 stars$6.24-89.9%$57.00+813.5%-81.7%$3.98BN/A-2.242Analyst ForecastAnalyst RevisionHigh Trading Volume Related Companies and Tools Related Companies Krystal Biotech Alternatives PTC Therapeutics Alternatives Jyong Biotech Alternatives Arrowhead Pharmaceuticals Alternatives Arcellx Alternatives Vaxcyte Alternatives Crinetics Pharmaceuticals Alternatives Protagonist Therapeutics Alternatives Kymera Therapeutics Alternatives MoonLake Immunotherapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TRML) was last updated on 10/9/2025 by MarketBeat.com Staff From Our PartnersMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tourmaline Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tourmaline Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
